NORDIOL-21

Κύριές Πληροφορίες

  • Εμπορική ονομασία:
  • NORDIOL-21 (50+125)MCG/TAB(ORC) C.TAB
  • Δοσολογία:
  • (50+125)MCG/TAB(ORC)
  • Φαρμακοτεχνική μορφή:
  • ΕΠΙΚΑΛΥΜΕΝΟ ΔΙΣΚΙΟ
  • Χρήση για:
  • Οι άνθρωποι
  • Τύπος φάρμακου:
  • αλλοπαθητική των ναρκωτικών

Έγγραφα

  • για το ευρύ κοινό:
  • Το ενημερωτικό φυλλάδιο για το προϊόν αυτό δεν είναι άμεσα διαθέσιμα, μπορείτε να στείλετε ένα αίτημα στην εξυπηρέτηση πελατών μας και εμείς θα σας ενημερώσουμε το συντομότερο είμαστε σε θέση να το αποκτήσει.


    Ζητήστε το ενημερωτικό φυλλάδιο για το ευρύ κοινό.

Εντοπισμός

  • Διατίθεται σε:
  • NORDIOL-21 (50+125)MCG/TAB(ORC) C.TAB
    Ελλάδα
  • Γλώσσα:
  • Ελληνικά

Θεραπευτικές πληροφορίες

  • Θεραπευτική περιοχή:
  • ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Άλλες πληροφορίες

Κατάσταση

  • Πηγή:
  • Εθνικός Οργανισμός Φαρμάκων
  • τελευταία ενημέρωση:
  • 09-08-2016
  • Το ενημερωτικό φυλλάδιο για το προϊόν αυτό δεν είναι άμεσα διαθέσιμα, μπορείτε να στείλετε ένα αίτημα στην εξυπηρέτηση πελατών μας και εμείς θα σας ενημερώσουμε το συντομότερο είμαστε σε θέση να το αποκτήσει.

    Ζητήστε το ενημερωτικό φυλλάδιο για το ευρύ κοινό.

22-3-2019

Safety and efficacy of l‐lysine monohydrochloride and l‐lysine sulfate produced using Corynebacterium glutamicum CCTCC M 2015595 for all animal species

Safety and efficacy of l‐lysine monohydrochloride and l‐lysine sulfate produced using Corynebacterium glutamicum CCTCC M 2015595 for all animal species

Published on: Thu, 21 Mar 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on l‐lysine monohydrochloride and l‐lysine sulfate produced using Corynebacterium glutamicum CCTCC M 2015595 when used as nutritional additive in feed and water for drinking for all animal species. The active substance is l‐lysine and it is produced in two different forms (monohydrochloride or sulfate). O...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-3-2019

Assessment of the application for renewal of authorisation of Levucell SC (Saccharomyces cerevisiae CNCM I‐1077) as a feed additive for lambs and horses

Assessment of the application for renewal of authorisation of Levucell SC (Saccharomyces cerevisiae CNCM I‐1077) as a feed additive for lambs and horses

Published on: Thu, 21 Mar 2019 Levucell® SC is the trade name for a feed additive based on viable cells of a strain Saccharomyces cerevisiae. The product is currently authorised for use in feed for horses, lambs, dairy sheep and dairy goats, dairy cows and cattle for fattening. This opinion concerns the renewal of the authorisation of Levucell® SC as a zootechnical additive for lambs and horses. S. cerevisiae is considered by EFSA to be suitable for the qualified presumption of safety (QPS) approach to ...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-3-2019

Evaluation of the applicability of existing (Q)SAR models for predicting the genotoxicity of pesticides and similarity analysis related with genotoxicity of pesticides for facilitating of grouping and read across

Evaluation of the applicability of existing (Q)SAR models for predicting the genotoxicity of pesticides and similarity analysis related with genotoxicity of pesticides for facilitating of grouping and read across

Published on: Thu, 21 Mar 2019 To facilitate the practical implementation of the guidance on the residue definition for dietary risk assessment, EFSA has organized an evaluation of applicability of existing in silico models for predicting the genotoxicity of pesticides and their metabolites, including analysis of the impact on genotoxicity of the metabolic structural changes. The prediction ability of (Q)SARs for in vitro and in vivo tests were evaluated. For the Ames test, all (Q)SAR models generated s...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-3-2019

Safety and efficacy of l‐tryptophan produced with Escherichia coli CGMCC 11674 for all animal species

Safety and efficacy of l‐tryptophan produced with Escherichia coli CGMCC 11674 for all animal species

Published on: Thu, 21 Mar 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on l‐tryptophan produced by fermentation with Escherichia coli CGMCC 11674 when used as a nutritional additive in feed and water for drinking for all animal species and categories. The production strain did not raise safety concerns. The FEEDAP Panel cannot conclude on the safety of l‐tryptophan produced ...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-3-2019

Lumpy skin disease III. Data collection and analysis

Lumpy skin disease III. Data collection and analysis

Published on: Thu, 21 Mar 2019 In 2018, no lumpy skin disease (LSD) outbreaks were reported in the Balkan region, after the decline reported in 2017 (385) compared to 2016 (7,483). This confirms the effectiveness of the vaccination campaign based on the LSD homologous vaccine strain which continued throughout 2018 with over 2.5 million animals vaccinated, keeping the mean vaccination coverage above 70%. In 2018, LSD outbreaks were reported in Russia, Turkey and Georgia. In Russia, the LSD epidemics expa...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019


Management Board meeting: 21 March 2019, European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2019 to 21/03/2019

Management Board meeting: 21 March 2019, European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2019 to 21/03/2019

Management Board meeting: 21 March 2019, European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2019 to 21/03/2019

Europe - EMA - European Medicines Agency

20-3-2019


Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 March 2019 , European Medicines Agency, Amsterdam, the Netherlands, from 19/03/2019 to 21/03/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 March 2019 , European Medicines Agency, Amsterdam, the Netherlands, from 19/03/2019 to 21/03/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 March 2019 , European Medicines Agency, Amsterdam, the Netherlands, from 19/03/2019 to 21/03/2019

Europe - EMA - European Medicines Agency

20-3-2019


Agenda - COMP agenda of the 19-21 March 2019 meeting

Agenda - COMP agenda of the 19-21 March 2019 meeting

Agenda - COMP agenda of the 19-21 March 2019 meeting

Europe - EMA - European Medicines Agency

21-2-2019

February 21, 2019: Traveling Nurse Who Worked in Roanoke Sentenced for Tampering with Fentanyl

February 21, 2019: Traveling Nurse Who Worked in Roanoke Sentenced for Tampering with Fentanyl

February 21, 2019: Traveling Nurse Who Worked in Roanoke Sentenced for Tampering with Fentanyl

FDA - U.S. Food and Drug Administration

20-2-2019


Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Europe - EMA - European Medicines Agency

26-1-2019

SL: Recall of Thrive Market Nut Butters Due to Potential Health Risk

SL: Recall of Thrive Market Nut Butters Due to Potential Health Risk

Thrive Market, Inc, is recalling all unexpired lots of the Thrive Market-branded nut butters listed below (“Product(s)”) due to the potential for contamination with Listeria monocytogenes. On January 21, 2019, one of our suppliers notified us that it was issuing a recall of all nut butters it has manufactured since January 2018 because of a positive test for Listeria monocytogenes in recent lots. Because the safety of our members is our absolute priority, we are expanding on our supplier’s recall and a...

FDA - U.S. Food and Drug Administration

22-1-2019

Modification of the existing maximum residue level for trifloxystrobin in broccoli

Modification of the existing maximum residue level for trifloxystrobin in broccoli

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Bayer Hellas AG submitted a request to the competent national authority in Greece to modify the existing maximum residue level (MRL) for the active substance trifloxystrobin in broccoli. The data submitted in support of the request were found to be sufficient to derive an MRL proposal for broccoli. Adequate analytical methods for enforcement are available to control the residues of trifloxystrobin o...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs

Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicants Landesanstalt für Landwirtschaft und Gartenbau Sachsen‐Anhalt (LSA) and Dienstleistungszentrum Ländlicher Raum Rheinpfalz (DLR), respectively, submitted a request to the competent national authority in Germany to modify the existing maximum residue levels (MRL) for the active substance aclonifen in chives, parsley, celery leaves/dill leaves, thyme/savoury and in celeriacs/turnip‐rooted celery. The ...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue levels for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds

Modification of the existing maximum residue levels for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Isagro S.p.A submitted a request to the competent national authority in Italy to modify the existing maximum residue levels (MRLs) for the active substance tetraconazole in various crops and animal commodities. The data submitted in support of the request were found to be sufficient to derive MRL proposals for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds. Adequate analytical me...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

SIGMA Animal Disease Data Model: A comprehensive approach for the collection of standardised data on animal diseases

SIGMA Animal Disease Data Model: A comprehensive approach for the collection of standardised data on animal diseases

Published on: Mon, 21 Jan 2019 The European Commission is routinely asking EFSA for scientific and technical support in the epidemiological analysis of animal disease outbreaks (i.e. African swine fever, lumpy skin disease and avian influenza) and to report or assess surveillance data (i.e. Echinococcus multilocularis and avian influenza). For this purpose, EFSA has over the last years carried out several data collections and gathered specific information on outbreaks, surveillance activities and concer...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Data sources on animal diseases: Country Card of Ireland

Data sources on animal diseases: Country Card of Ireland

Published on: Mon, 21 Jan 2019 Mapping ‘data sources’ on animal diseases in each European Union (EU) Member State is one of the activities of EFSA's SIGMA1,2 ;project. The aim of this activity is to identify the central competent authorities responsible for managing the data on animal diseases and animal populations in each Member State. Initially EFSA is focusing on three diseases (on which EFSA is currently working): African swine fever, avian influenza and lumpy skin disease; and on the corresponding...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Peer review of the pesticide risk assessment of the active substance fenamiphos

Peer review of the pesticide risk assessment of the active substance fenamiphos

Published on: Mon, 21 Jan 2019 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Greece and co‐rapporteur Member State Cyprus for the pesticide active substance fenamiphos are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of fenamiphos as a nematic...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Modification of the existing maximum residue levels for aminopyralid in certain cereals

Modification of the existing maximum residue levels for aminopyralid in certain cereals

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Dow AgroSciences Denmark submitted a request to the competent national authority in the United Kingdom to modify the existing maximum residue levels (MRLs) for the active substance aminopyralid in cereals. The data submitted in support of the request were found to be sufficient to derive MRL proposals for barley, rye, sorghum, millet and oats. A modification of the existing MRL of aminopyralid in wh...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-1-2019

Enforcement Report for the Week of January 09, 2019

Enforcement Report for the Week of January 09, 2019

Recently Updated Records for the Week of January 09, 2019 Last Modified Date: Monday, January 21, 2019

FDA - U.S. Food and Drug Administration

19-1-2019

Ottogi America, Inc. Issues Allergy Alert on Undeclared Egg in Products

Ottogi America, Inc. Issues Allergy Alert on Undeclared Egg in Products

Ottogi America, Inc. announced today it is recalling below 21 items due to a possibility of containing egg ingredient undeclared on the packages. People who have an allergy or severe sensitivity to eggs run the risk of serious or life-threatening allergic reaction of they consume these products.

FDA - U.S. Food and Drug Administration

26-12-2018

Enforcement Report for the Week of December 26, 2018

Enforcement Report for the Week of December 26, 2018

Recently Updated Records for the Week of December 26, 2018 Last Modified Date: Friday, December 21, 2018

FDA - U.S. Food and Drug Administration

22-12-2018

Modification of the existing maximum residue level for captan in hops

Modification of the existing maximum residue level for captan in hops

Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant ADAMA Agriculture BV on behalf of ADAMA Makhteshim Ltd. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue level for the active substance captan in hops. The data submitted in support of the request were found to be insufficient to conclude whether the existing residue definitions are appropriate for hops. Although the number of residue ...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-12-2018

Modification of the existing maximum residue level for captan in cranberries

Modification of the existing maximum residue level for captan in cranberries

Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the Belgian Federal Public Service (FPS) for Health, Food chain safety and Environment, submitted an application as the competent national authority in Belgium to modify the existing maximum residue level (MRL) for the active substance captan in cranberries. The data submitted in support of the request were found to be sufficient to derive MRL proposal for cranberries. Adequate analytical methods for enforcement ...

Europe - EFSA - European Food Safety Authority EFSA Journal

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

30-11-2018

The European Union summary report on surveillance for the presence of transmissible spongiform encephalopathies (TSEs) in 2017

The European Union summary report on surveillance for the presence of transmissible spongiform encephalopathies (TSEs) in 2017

Published on: Thu, 29 Nov 2018 This report presents the results of surveillance on transmissible spongiform encephalopathies (TSEs) in bovine animals, sheep, goats, cervids and other animal species, as well as genotyping in sheep, carried out in 2017 in the European Union (EU) according to Regulation (EC) 999/2001, and in Iceland, Norway and Switzerland. In total, 1,312,714 cattle were tested by the 28 EU Member States (MSs) which is a decrease of 3% compared with 2016; 18,526 were tested by the three n...

Europe - EFSA - European Food Safety Authority Publications

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

15-3-2019


Orphan designation: exenatide, Treatment of idiopathic intracranial hypertension, 21/03/2016, Positive

Orphan designation: exenatide, Treatment of idiopathic intracranial hypertension, 21/03/2016, Positive

Orphan designation: exenatide, Treatment of idiopathic intracranial hypertension, 21/03/2016, Positive

Europe - EMA - European Medicines Agency

7-3-2019


Orphan designation: Adeno-associated viral vector expressing human 21- hydroxylase, Treatment of congenital adrenal hyperplasia, 14/12/2018, Positive

Orphan designation: Adeno-associated viral vector expressing human 21- hydroxylase, Treatment of congenital adrenal hyperplasia, 14/12/2018, Positive

Orphan designation: Adeno-associated viral vector expressing human 21- hydroxylase, Treatment of congenital adrenal hyperplasia, 14/12/2018, Positive

Europe - EMA - European Medicines Agency

4-3-2019


Orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (lumasiran), Treatment of primary hyperoxaluria, 21/03/2016,

Orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (lumasiran), Treatment of primary hyperoxaluria, 21/03/2016,

Orphan designation: Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (lumasiran), Treatment of primary hyperoxaluria, 21/03/2016, Positive

Europe - EMA - European Medicines Agency

22-2-2019


Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Europe - EMA - European Medicines Agency

22-2-2019


Summary of opinion: ReproCyc ParvoFLEX,porcine parvovirosis vaccine (inactivated),  21/02/2019,  Positive

Summary of opinion: ReproCyc ParvoFLEX,porcine parvovirosis vaccine (inactivated), 21/02/2019, Positive

Summary of opinion: ReproCyc ParvoFLEX,porcine parvovirosis vaccine (inactivated), 21/02/2019, Positive

Europe - EMA - European Medicines Agency

22-2-2019


Summary of opinion: Forceris,toltrazuril,gleptoferron,  21/02/2019,  Positive

Summary of opinion: Forceris,toltrazuril,gleptoferron, 21/02/2019, Positive

Summary of opinion: Forceris,toltrazuril,gleptoferron, 21/02/2019, Positive

Europe - EMA - European Medicines Agency

22-2-2019


Summary of opinion: HorStem,equine umbilical cord mesenchymal stem cells,  21/02/2019,  Positive

Summary of opinion: HorStem,equine umbilical cord mesenchymal stem cells, 21/02/2019, Positive

Summary of opinion: HorStem,equine umbilical cord mesenchymal stem cells, 21/02/2019, Positive

Europe - EMA - European Medicines Agency

22-2-2019

Voriconazole Accord (Accord Healthcare S.L.U.)

Voriconazole Accord (Accord Healthcare S.L.U.)

Voriconazole Accord (Active substance: voriconazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1581 of Fri, 22 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2669/T/21

Europe -DG Health and Food Safety

22-2-2019


Orphan designation: Adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cells, Treatment of thromboangiitis obliterans (Buerger's disease), 21/05/2015, Positive

Orphan designation: Adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cells, Treatment of thromboangiitis obliterans (Buerger's disease), 21/05/2015, Positive

Orphan designation: Adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cells, Treatment of thromboangiitis obliterans (Buerger's disease), 21/05/2015, Positive

Europe - EMA - European Medicines Agency

21-2-2019


Orphan designation: Chimeric monoclonal antibody against GD2 (dinutuximab), Treatment of neuroblastoma, 21/06/2011, Withdrawn

Orphan designation: Chimeric monoclonal antibody against GD2 (dinutuximab), Treatment of neuroblastoma, 21/06/2011, Withdrawn

Orphan designation: Chimeric monoclonal antibody against GD2 (dinutuximab), Treatment of neuroblastoma, 21/06/2011, Withdrawn

Europe - EMA - European Medicines Agency

21-2-2019


Orphan designation: Celecoxib, Treatment of familial adenomatous polyposis (FAP), 21/11/2001, Withdrawn

Orphan designation: Celecoxib, Treatment of familial adenomatous polyposis (FAP), 21/11/2001, Withdrawn

Orphan designation: Celecoxib, Treatment of familial adenomatous polyposis (FAP), 21/11/2001, Withdrawn

Europe - EMA - European Medicines Agency

21-2-2019

Rebif (Merck Europe B.V.)

Rebif (Merck Europe B.V.)

Rebif (Active substance: Interferon beta-1a) - Corrigendum - Commission Decision (2019)1535 of Thu, 21 Feb 2019

Europe -DG Health and Food Safety

20-2-2019


Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201807

Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201807

Levonorgestrel / ethinylestradiol, ethinylestradiol (combination pack): List of nationally authorised medicinal products - PSUSA/00010442/201807

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Orphan designation: 2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide, Treatment of cystic fibrosis, 21/05/2015, Positive

Europe - EMA - European Medicines Agency

7-2-2019

Consultation: Reforms to the generic medicine market authorisation process

Consultation: Reforms to the generic medicine market authorisation process

The TGA is seeking comments from interested parties on the proposed generic medicines reforms. Closing date: 21 March 2019

Therapeutic Goods Administration - Australia

25-1-2019


Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Orphan designation: Sulfonated monophosphorylated mannose oligosaccharide, Treatment of hepatocellular carcinoma, 21/06/2011, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Orphan designation: Triamcinolone acetonide, Treatment of non-infectious uveitis, 21/05/2015, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Europe - EMA - European Medicines Agency

21-1-2019

bimatoprost

bimatoprost

bimatoprost (Active substance: bimatoprost) - Centralised - Art 28 - (PSUR - Commission Decision C(2019) 591 of Mon, 21 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/413/201803

Europe -DG Health and Food Safety

21-1-2019

Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names

Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names

Diclofenac Sodium Spray Gel 4 % Cutaneous Spray, Solution and associated names (Active substance: Diclofenac sodium) - Community Referrals - Art 29 - Commission Decision (2019)589 of Mon, 21 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/A-29(4)/1467

Europe -DG Health and Food Safety

17-1-2019

Holoclar (Chiesi Farmaceutici S.p.A.)

Holoclar (Chiesi Farmaceutici S.p.A.)

Holoclar (Active substance: Ex vivo expanded autologous human corneal epithelial cells containing stem cells) - Centralised - Annual renewal - Commission Decision (2019)272 of Thu, 17 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2450/R/21

Europe -DG Health and Food Safety

16-1-2019

EU/3/14/1309 (Pharma Gateway AB)

EU/3/14/1309 (Pharma Gateway AB)

EU/3/14/1309 (Active substance: 17a,21-dihydroxy-16a-methyl-pregna-1,4,9(11)-triene-3,20-dione) - Transfer of orphan designation - Commission Decision (2019)232 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002736

Europe -DG Health and Food Safety

19-12-2018

EU/3/14/1423 (Richardson Associates Regulatory Affairs Ltd)

EU/3/14/1423 (Richardson Associates Regulatory Affairs Ltd)

EU/3/14/1423 (Active substance: Synthetic signal peptide of human mucin-1 (amino acids 1-21)) - Transfer of orphan designation - Commission Decision (2018)9009 of Wed, 19 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002647

Europe -DG Health and Food Safety

19-12-2018


European Medicines Agency closed 21 December 2018 to 2 January 2019

European Medicines Agency closed 21 December 2018 to 2 January 2019

European Medicines Agency closed 21 December 2018 to 2 January 2019

Europe - EMA - European Medicines Agency

18-12-2018

EU/3/18/2108 (Pharma Gateway AB)

EU/3/18/2108 (Pharma Gateway AB)

EU/3/18/2108 (Active substance: Adeno-associated viral vector expressing human 21-hydroxylase) - Orphan designation - Commission Decision (2018)9023 of Tue, 18 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/18

Europe -DG Health and Food Safety

12-12-2018

Consultation: Proposed amendments to the Poisons Standard - ACCS, ACMS and Joint ACCS/ACMS meetings, March 2019

Consultation: Proposed amendments to the Poisons Standard - ACCS, ACMS and Joint ACCS/ACMS meetings, March 2019

Proposed Amendments to the Poisons Standard are now available for public comment. Closing date: 21 January 2019

Therapeutic Goods Administration - Australia

12-12-2018

Oncaspar (Les Laboratoires Servier)

Oncaspar (Les Laboratoires Servier)

Oncaspar (Active substance: pegaspargase) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8757 of Wed, 12 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3789/T/21

Europe -DG Health and Food Safety

12-12-2018

Elocta (Swedish Orphan Biovitrum AB (publ))

Elocta (Swedish Orphan Biovitrum AB (publ))

Elocta (Active substance: efmoroctocog alfa) - Centralised - Variation - Commission Decision (2018)8678 of Wed, 12 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3964/X/21

Europe -DG Health and Food Safety

26-11-2018

Mirvaso (Galderma International)

Mirvaso (Galderma International)

Mirvaso (Active substance: brimonidine) - Centralised - Renewal - Commission Decision (2018)7977 of Mon, 26 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2642/R/21

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2081 (Pharma Gateway AB)

EU/3/18/2081 (Pharma Gateway AB)

EU/3/18/2081 (Active substance: 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid) - Orphan designation - Commission Decision (2018)7790 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/096/18

Europe -DG Health and Food Safety

21-11-2018

Rheumocam (Chanelle Pharmaceuticals Manufacturing Limited)

Rheumocam (Chanelle Pharmaceuticals Manufacturing Limited)

Rheumocam (Active substance: Meloxicam) - Centralised - Variation - Commission Decision (2018)7841 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/121/X/22

Europe -DG Health and Food Safety

21-11-2018

EU/3/15/1567 (TMC Pharma (EU) Limited)

EU/3/15/1567 (TMC Pharma (EU) Limited)

EU/3/15/1567 (Active substance: Recombinant human interleukin-3 truncated diphtheria toxin fusion protein) - Transfer of orphan designation - Commission Decision (2018)7816 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/064/15/T/02

Europe -DG Health and Food Safety

21-11-2018

EU/3/17/1962 (MWB Consulting S.A.R.L.)

EU/3/17/1962 (MWB Consulting S.A.R.L.)

EU/3/17/1962 (Active substance: Humanised Fc-engineered monoclonal antibody against CD19) - Transfer of orphan designation - Commission Decision (2018)7815 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/155/17/T/01

Europe -DG Health and Food Safety

21-11-2018

Osurnia (Elanco GmbH)

Osurnia (Elanco GmbH)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7842 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/003753/T/0010

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2102 (IQVIA RDS Ireland Limited)

EU/3/18/2102 (IQVIA RDS Ireland Limited)

EU/3/18/2102 (Active substance: Apraglutide) - Orphan designation - Commission Decision (2018)7812 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/115/18

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2101 (TMC Pharma Services Ltd)

EU/3/18/2101 (TMC Pharma Services Ltd)

EU/3/18/2101 (Active substance: Setmelanotide) - Orphan designation - Commission Decision (2018)7811 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/143/18

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2100 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/2100 (Quality Regulatory Clinical Ireland Limited)

EU/3/18/2100 (Active substance: Propagermanium) - Orphan designation - Commission Decision (2018)7810 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/103/18

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2099 (Celgene Europe Limited)

EU/3/18/2099 (Celgene Europe Limited)

EU/3/18/2099 (Active substance: Lisocabtagene maraleucel) - Orphan designation - Commission Decision (2018)7809 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/124/18

Europe -DG Health and Food Safety